Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
William Guyer to join Corcept as Chief Development Officer
05:00pm, Thursday, 12'th Aug 2021
MENLO PARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met
Corcept's (CORT) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
03:12pm, Friday, 30'th Jul 2021
Corcept (CORT) beats on both earnings and revenues in the second quarter of 2021. The company maintains the revenue guidance for 2021.
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q2 2021 Results - Earnings Call Transcript
11:33pm, Thursday, 29'th Jul 2021
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q2 2021 Results - Earnings Call Transcript
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
04:05pm, Thursday, 29'th Jul 2021
MENLO PARK, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met
CORT or ZTS: Which Is the Better Value Stock Right Now?
01:51pm, Tuesday, 27'th Jul 2021
CORT vs. ZTS: Which Stock Is the Better Value Option?
Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Thursday, 22'nd Jul 2021
MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on
Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer
08:30am, Monday, 12'th Jul 2021
MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met
Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer
10:36am, Tuesday, 22'nd Jun 2021
Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer. The trial evaluated relacorilant
Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
08:30am, Tuesday, 22'nd Jun 2021
MENLO PARK, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met
Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical
08:30am, Tuesday, 15'th Jun 2021
MENLO PARK, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met
Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors
07:30am, Thursday, 10'th Jun 2021
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met
Corcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition
09:46am, Friday, 14'th May 2021
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well.
Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y
11:16am, Friday, 07'th May 2021
Corcept (CORT) reports wider-than-expected loss in the first quarter of 2021, with its revenues also missing estimates.
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2021 Results - Earnings Call Transcript
09:40am, Friday, 07'th May 2021
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2021 Results - Earnings Call Transcript
Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates
06:01pm, Thursday, 06'th May 2021
Corcept (CORT) delivered earnings and revenue surprises of -14.29% and -18.53%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
